Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8216 results

  1. Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media

    In development [GID-NG10410] Expected publication date: 16 October 2024

    NICE guideline
    In development

  2. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    Awaiting development [GID-TA11025] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tirzepatide for managing overweight and obesity [ID6179]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 25 June 2024.

    Technology appraisal guidance
    In consultation

  5. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device

    In development [GID-DG10080] Expected publication date: 22 August 2024

    Diagnostics guidance
    In development

  6. Transcatheter aortic valve implantation for aortic incompetence

    Awaiting development [GID-IPG10357] Expected publication date: 11 June 2025

    Interventional procedures guidance
    Awaiting development

  7. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    Awaiting development [GID-TA11466] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    Awaiting development [GID-TA11278] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 11 September 2024

    Diagnostics guidance
    In development

  12. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  13. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  14. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 27 June 2024.

    Technology appraisal guidance
    In consultation

  15. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940

      Status ...

    Technology appraisal guidance
    Topic selection